You are here

FDA Warns of Cardiovascular Events With Bioresorbable Stent

Procedure should be avoided in small heart vessels

The FDA is informing health care providers treating patients with the Absorb GT1 bioresorbable vascular scaffold (BVS) (Abbott Vascular) that an increased rate of major adverse cardiac events has been observed in patients receiving the BVS compared with patients treated with the metallic Xience drug-eluting stent (Abbott Vascular).

The Absorb GT1 BVS is used to open coronary arteries blocked by scar tissue (plaque) in order to increase blood flow to the heart muscle. The BVS is implanted during an angioplasty procedure. It gradually dissolves and is fully absorbed by the body over time.

The FDA’s initial review of two-year data from the pivotal ABSORB III trial found an 11.0% rate of major adverse cardiac events (e.g., cardiac death, heart attack, or the need for an additional procedure to reopen the treated heart vessel) in patients treated with the BVS at two years compared with 7.9% in patients treated with the metallic Xience drug-eluting stent (P = 0.03). This study also showed a 1.9% rate of thrombosis within the BVS compared with a 0.8% rate within the Xience stent at two years. These observed higher adverse cardiac event rates in BVS patients were more likely when the device was placed in small heart vessels.

In its report on the trial results, Abbott stated: “The ABSORB III study began in 2012, and since then, training on the device has evolved based on learnings in the medical community and physician experience. When Absorb was approved by the U.S. Food and Drug Administration in July 2016, the instructions for use specified the avoidance of very small vessels and included optimal implantation guidelines.”

The FDA is working with Abbott Vascular to conduct additional analyses to better understand the cause(s) of the higher cardiac event and device thrombosis rates in patients treated with the BVS compared with the Xience stent. Meanwhile, the agency recommends that health care providers:

  • Follow the instructions for target heart vessel selection (e.g., avoid BVS use in small heart vessels) and optimal device implantation that are included in the BVS labeling.
  • Advise patients experiencing new cardiac symptoms, such as irregular heartbeats, chest pain, or shortness of breath, to seek clinical care.
  • Advise BVS patients to follow the recommendations for DAPT prescribed by their health care providers.
  • Report to Medwatch any adverse events related to the BVS that come to their attention.

Sources: FDA; March 18, 2017; and Abbott; March 18, 2017.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs